astrazeneca-pharma

by hanxueyuan

Install this Skill

curl -fsSL -o astrazeneca-pharma.zip https://skill.seembox.com/api/v1/skills/astrazeneca-pharma/download && unzip astrazeneca-pharma.zip

Download astrazeneca-pharma.zip

SKILL.md About

---
title: AstraZeneca
summary: "Anglo-Swedish pharmaceutical giant formed by merger, pioneering oncology treatments and co-developing one of the world's most widely deployed COVID-19 vaccines."
read_when:
  - Researching pharmaceutical industry consolidation
  - Analyzing oncology drug pipeline strategies
  - Studying COVID-19 vaccine development and distribution
  - Comparing pharma R&D productivity
---

# AstraZeneca

Anglo-Swedish pharmaceutical giant formed by merger, pioneering oncology treatments and co-developing one of the world's most widely deployed COVID-19 vaccines.

## 历史时间线

- 1999: Astra AB (Sweden) merges with Zeneca Group (UK) to form AstraZeneca
- 2007: Acquires MedImmune for $15.6B — enters biologics
- 2014: Rejects $120B Pfizer takeover bid
- 2020: Co-develops Oxford-AstraZeneca COVID-19 vaccine — 3B+ doses distributed globally
- 2020: Acquires Alexion for $39B — rare disease expansion
- 2022: Acquires Daiichi Sankyo partnership for Enhertu (breast cancer)
- 2023: $45B+ revenue; oncology = 40%+ of pipeline

## 商业模式

R&D-driven pharma with focus on oncology, cardiovascular, renal/metabolism, and respiratory/immunology. Revenue from prescription drug sales globally. Alexion acquisition adds rare disease (complement inhibitors). Oxford vaccine developed at-cost for pandemic, building long-term government relationships.

## 护城河分析

Oncology pipeline depth (Enhertu, Tagrisso, Imfinzi); Alexion's rare disease dominance (complement pathway); Oxford partnership for vaccine tech; strong presence in emerging markets (China, Asia); biosimilar strategy for post-patent products.

## 关键数据

- revenue: $45B+ (2023)
- oncology_share: 40%+ of pipeline
- vaccine_doses: 3B+ (Oxford-AZ vaccine)
- employees: ~90,000
- market_cap: ~$200B

## 有趣事实

The Oxford-AstraZeneca vaccine was unique in being developed at non-profit cost for low-income countries during the pandemic — AstraZeneca pledged not to profit from it during the emergency. The vaccine used a chimpanzee adenovirus vector (ChAdOx1) technology pioneered at Oxford University.

_meta.json Metadata

{
  "ownerId": "kn783tv7jyap70kp5ap5wfq4rx82sqqg",
  "publishedAt": 1778148297622,
  "slug": "astrazeneca-pharma",
  "version": "1.0.0"
}